- Details
- Description
-
Packaging Size30t/bottle
-
Strength15mg&45mg
-
CompositonDacomitinib
-
TreatmentEGFR exon 19 deletions or exon 21 (L858R) substitution mutations non-small cell lung cancer (NSCLC)
-
FormTablet
-
BrandLuciDac
-
Quantity Unit15mg*30T/Bottle&45mg*30T/Bottle
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
INDICATIONS AND USAGE
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
DOSAGE AND ADMINISTRATION
Recommended Dosage: 45 mg orally once daily with or without food.